Foregoing intracardiac electrophysiologic mapping was as good as conventional cryoablation with pulmonary vein (PV) mapping in the AVATAR-HF* study, suggesting that a simplified procedure could produce the same outcomes for lower costs.
Use of uninterrupted edoxaban during catheter ablation for atrial fibrillation (AF) shows comparable safety and efficacy as uninterrupted vitamin K antagonists (VKAs), according to the ELIMINATE-AF trial presented at EHRA 2019.
Patients on the anticoagulant drug edoxaban could safely continue their treatment while undergoing certain procedures, with a low incidence of bleeding and cardiovascular events reported in the prospective EMIT AF/VTE* study.
Remote monitoring (RM) reduced hospitalization rates in patients with heart failure (HF) and implanted cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D), according to data from the RESULT* trial presented at EHRA 2019.
Patients who have recently experienced atrial fibrillation (AF) could benefit from treatment with upfront rate-control medication rather than undergoing immediate cardioversion to restore sinus rhythm, according to The Netherlands-based RACE 7 ACWAS* trial.
A two-part tilt training programme designed to retrain the autonomic nervous system (ANS) to respond correctly to move to an upright position effectively prevented reflex syncope (RS) or fainting episodes, offering patients an improved quality of life (QoL) and ability to return to work, according to data presented at EHRA 2019.
Use of high doses of the dihydropyridine nifedipine was associated with a higher risk of out-of-hospital cardiac arrest (OHCA) than nonuse of dihydropyridines, according to data from two large registries under the ESCAPE-NET* presented at EHRA Congress 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.